These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7235381)

  • 1. The hepatotoxicity of isoniazid among the three acetylator phenotypes.
    Ellard GA; Girling DJ; Nunn AJ
    Am Rev Respir Dis; 1981 May; 123(5):568-70. PubMed ID: 7235381
    [No Abstract]   [Full Text] [Related]  

  • 2. Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis.
    Gurumurthy P; Krishnamurthy MS; Nazareth O; Parthasarathy R; Sarma GR; Somasundaram PR; Tripathy SP; Ellard GA
    Am Rev Respir Dis; 1984 Jan; 129(1):58-61. PubMed ID: 6367570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis.
    Grönhagen-Riska C; Hellstrom PE; Fröseth B
    Am Rev Respir Dis; 1978 Sep; 118(3):461-6. PubMed ID: 707874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of two pulmonary tuberculosis drug treatments and acetylator status on liver function in a Zimbabwean population.
    Neill P; Pringle D; Mhonda M; Kusema T; Nhachi CF
    Cent Afr J Med; 1990 Apr; 36(4):104-7. PubMed ID: 2225025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Side-effects in chemotherapy of pulmonary tuberculosis].
    Savula MM; Smachilo DT; Kiselova ES
    Probl Tuberk; 1976 Feb; (21):39-43. PubMed ID: 1264981
    [No Abstract]   [Full Text] [Related]  

  • 6. Hepatotoxicity of rifampicin and isoniazid in children treated for tuberculosis.
    Linna O; Uhari M
    Eur J Pediatr; 1980 Sep; 134(3):227-9. PubMed ID: 6968680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis.
    Ellard GA
    Tubercle; 1984 Sep; 65(3):211-27. PubMed ID: 6385429
    [No Abstract]   [Full Text] [Related]  

  • 8. Association of isoniazid-metabolizing enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients.
    Sotsuka T; Sasaki Y; Hirai S; Yamagishi F; Ueno K
    In Vivo; 2011; 25(5):803-12. PubMed ID: 21753138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isoniazid hepatotoxicity and acetylation during tuberculosis chemoprophylaxis.
    Myles RK
    Am Rev Respir Dis; 1980 Sep; 122(3):505-6. PubMed ID: 6106445
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels.
    Jeong I; Park JS; Cho YJ; Yoon HI; Song J; Lee CT; Lee JH
    J Korean Med Sci; 2015 Feb; 30(2):167-72. PubMed ID: 25653488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis.
    Mitchell JR; Zimmerman HJ; Ishak KG; Thorgeirsson UP; Timbrell JA; Snodgrass WR; Nelson SD
    Ann Intern Med; 1976 Feb; 84(2):181-92. PubMed ID: 766682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isoniazid hepatotoxicity in children.
    Rapp RS; Campbell RW; Howell JC; Kendig EL
    Am Rev Respir Dis; 1978 Oct; 118(4):794-6. PubMed ID: 309296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hepatotoxicity of thiacetazone].
    Volek V; Vodrázková A; Polánský F; Lukes J
    Cas Lek Cesk; 1970 May; 109(23):529-32. PubMed ID: 4192343
    [No Abstract]   [Full Text] [Related]  

  • 14. Isoniazid plus rifampicin in the initial treatment of pulmonary tuberculosis.
    Clarke GB; Cuthbert J; Cuthbert RJ; Lees AW
    Br J Dis Chest; 1972 Oct; 66(4):268-71. PubMed ID: 5083434
    [No Abstract]   [Full Text] [Related]  

  • 15. Acetylation phenotype and hepatotoxicity in the treatment of tuberculosis in children.
    Martinez-Roíg A; Camí J; Llorens-Terol J; de la Torre R; Perich F
    Pediatrics; 1986 Jun; 77(6):912-5. PubMed ID: 3487069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatotoxic reactions in children with severe tuberculosis treated with isoniazid-rifampin.
    Tsagaropoulou-Stinga H; Mataki-Emmanouilidou T; Karida-Kavalioti S; Manios S
    Pediatr Infect Dis; 1985; 4(3):270-3. PubMed ID: 4000989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Incidence of hepatotoxic side effects during antituberculous therapy (INH, RMP, EMB) in relation to the acetylator phenotype (author's transl)].
    Musch E; Eichelbaum M; Wang JK; von Sassen W; Castro-Parra M; Dengler HJ
    Klin Wochenschr; 1982 May; 60(10):513-9. PubMed ID: 7098379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isoniazid hepatitis: are immunological mechanisms implicated?
    Martínez-Tadeo JA; González-Pérez R; Hernández-Santana G
    Allergol Immunopathol (Madr); 2010; 38(4):228. PubMed ID: 20227157
    [No Abstract]   [Full Text] [Related]  

  • 19. Hepatic function in relation to acetylator phenotype in children treated with antitubercular drugs.
    Seth V; Beotra A
    Indian J Med Res; 1989 Sep; 89():306-9. PubMed ID: 2628292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aging and hepatotoxicity of isoniazid and rifampin in pulmonary tuberculosis.
    van den Brande P; van Steenbergen W; Vervoort G; Demedts M
    Am J Respir Crit Care Med; 1995 Nov; 152(5 Pt 1):1705-8. PubMed ID: 7582317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.